{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:51:38Z","timestamp":1772250698157,"version":"3.50.1"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,7,1]]},"DOI":"10.18632\/oncotarget.28467","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:25:55Z","timestamp":1688214355000},"page":"688-699","source":"Crossref","is-referenced-by-count":2,"title":["Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin"],"prefix":"10.18632","volume":"14","author":[{"given":"Joel","family":"Ohana","sequence":"first","affiliation":[{"name":"Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uziel","family":"Sandler","sequence":"additional","affiliation":[{"name":"Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel"},{"name":"Department of Bio-Informatics, Lev Academic Center (JCT), Jerusalem 91160, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orly","family":"Devary","sequence":"additional","affiliation":[{"name":"Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Devary","sequence":"additional","affiliation":[{"name":"Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"RE13","DOI":"10.1126\/stke.2502004re13","article-title":"Human RAS superfamily proteins and related GTPases","volume":"200","author":"Colicelli","year":"2004","journal-title":"Sci STKE"},{"key":"2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1242\/jcs.01660","article-title":"The Ras superfamily at a glance","volume":"11","author":"Der","year":"2005","journal-title":"J Cell Sci"},{"key":"3","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1073\/pnas.80.8.2112","article-title":"Three human transforming genes are related to the viral ras oncogenes","volume":"8","author":"Wigler","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/302079a0","article-title":"Characterization of a human colon\/lung carcinoma oncogene","volume":"30","author":"Weinberg","year":"1983","journal-title":"Nature"},{"key":"5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1146\/annurev.bi.56.070187.004023","article-title":"ras genes","volume":"5","author":"Barbacid","year":"1987","journal-title":"Annu Rev Biochem"},{"key":"6","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1073\/pnas.79.16.4848","article-title":"Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses","volume":"7","author":"Lowy","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1093\/nar\/11.23.8221","article-title":"Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells","volume":"1","author":"Aaronson","year":"1983","journal-title":"Nucleic Acids Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"e7464","DOI":"10.1371\/journal.pone.0007464","article-title":"Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells","volume":"4","author":"Wistuba","year":"2009","journal-title":"PLoS One"},{"key":"9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"17","author":"McCormick","year":"2017","journal-title":"Cell"},{"key":"10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Fu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"11","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The Frequency of Ras Mutations in Cancer","volume":"8","author":"Hartley","year":"2020","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/348125a0","article-title":"The GTPase superfamily: a conserved switch for diverse cell functions","volume":"34","author":"McCormick","year":"1990","journal-title":"Nature"},{"key":"13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/349117a0","article-title":"The GTPase superfamily: conserved structure and molecular mechanism","volume":"34","author":"McCormick","year":"1991","journal-title":"Nature"},{"key":"14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants","volume":"27","author":"Wittinghofer","year":"1997","journal-title":"Science"},{"key":"15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2019.12.013","article-title":"Mutant KRAS at the Heart of Tumor Immune Evasion","volume":"5","author":"Downward","year":"2020","journal-title":"Immunity"},{"key":"16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cllc.2014.09.005","article-title":"Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer","volume":"1","author":"Sher","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"17","unstructured":"FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. U.S. Food & Drug. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-adagrasib-kras-g12c-mutated-nsclc."},{"key":"18","unstructured":"FDA grants accelerated approval to sotorasib for KRAS G12C-mutated NSCLC. U.S. Food & Drug. 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc."},{"key":"19","first-page":"327","article-title":"NEROFE--a novel human hormone-peptide with anti-cancer activity","volume":"8","author":"Devary","year":"2010","journal-title":"J Exp Ther Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3892\/mco.2017.1453","article-title":"dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of Golgi function","volume":"7","author":"Devary","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3892\/mco.2017.1505","article-title":"A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced\/metastatic solid tumors","volume":"8","author":"Devary","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/jir.2018.0044","article-title":"Interleukin-33 and ST2 Signaling in Tumor Microenvironment","volume":"3","author":"Lin","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"e00436","DOI":"10.1016\/j.heliyon.2017.e00436","article-title":"ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant","volume":"3","author":"Yanagisawa","year":"2017","journal-title":"Heliyon"},{"key":"24","doi-asserted-by":"publisher","first-page":"33353","DOI":"10.1038\/srep33353","article-title":"Identification of Doxorubicin as an Inhibitor of the IRE1\u03b1-XBP1 Axis of the Unfolded Protein Response","volume":"6","author":"Koong","year":"2016","journal-title":"Sci Rep"},{"key":"25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"2","author":"Lalezari","year":"2019","journal-title":"Nat Med"},{"key":"26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.biocel.2011.10.012","article-title":"Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics","volume":"4","author":"Lavandero","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/carcin\/bgq160","article-title":"The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS","volume":"3","author":"Chen","year":"2010","journal-title":"Carcinogenesis"},{"key":"28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semcancer.2015.04.010","article-title":"Targeting the IRE1\u03b1-XBP1 branch of the unfolded protein response in human diseases","volume":"3","author":"Koong","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"29","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","article-title":"ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis","volume":"16","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"30","doi-asserted-by":"publisher","first-page":"45495","DOI":"10.1074\/jbc.M406933200","article-title":"CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells","volume":"27","author":"Wang","year":"2004","journal-title":"J Biol Chem"},{"key":"31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cancers11030338","article-title":"Chemotherapy Resistance Explained through Endoplasmic Reticulum Stress-Dependent Signaling","volume":"1","author":"Yoon","year":"2019","journal-title":"Cancers (Basel)"},{"key":"32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/cancers14051321","article-title":"Direct TargetingMutation in Non-Small Cell Lung Cancer: Focus on Resistance","volume":"1","author":"Beau-Faller","year":"2022","journal-title":"Cancers (Basel)"},{"key":"33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"2","author":"Tang","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"34","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.jtocrr.2021.100213","article-title":"Severe Immune Checkpoint Inhibitor Hepatitis inG12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report","volume":"2","author":"Popat","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"35","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASInhibition","volume":"2","author":"Corcoran","year":"2020","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"59","author":"Roy","year":"2021","journal-title":"Nature"},{"key":"37","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASInhibition in Cancer","volume":"38","author":"Persky","year":"2021","journal-title":"N Engl J Med"},{"key":"38","unstructured":"TargetScanHuman 7.2. 2023. https:\/\/www.targetscan.org\/vert_72\/."}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:26:01Z","timestamp":1688214361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7,1]]}},"alternative-id":["28467"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28467","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}